18 research outputs found
The Bell Child: A YA Horror Novel
No full textThe Bell Child is a YA novel that centers around themes of loneliness and friendship, set against a backdrop of technology rooting its way into our organic places.Embargo status: Restricted until 09/2173. To request the author grant access, click
on the PDF link to the left
To an Indiscernible Heart
No full textTo an Indiscernible Heart compiles visual art and poems to explore the author\u27s experiences with anxiety, grief, relationships, and learning how to navigate change and life lessons. Themes travel across four sections, each marked by a different piece of visual art: \u27Trip into the Unsaid,\u27 \u27Sugarcoat,\u27 \u27Undertow Confessions,\u27 and \u27Speed Painting through Comfort Zones.\u27 Featuring craft elements including enjambment, repetition, and erasure, the collection pulls readers into the rocky nature of learning how to human
AESI Background Rates Literature Review & Visualitzation for Encephalitis
No full textAESI Background Rates Literature Review & Visualitzation for EncephalitisThe SPEAC Project is funded in whole by CEPI
Recommended from our members
Use of CONSORT Criteria for Reporting Randomized Controlled Trials in Pharmacy Journals
No full textClass of 2012 AbstractSpecific Aims: To explore whether publishing requirements for human-centered randomized control trials, particularly the CONSORT criteria, have any relationship to impact as measured by the Journal Citation Reports ™ Impact Factor. Methods: A worksheet was used to evaluate a methodically selected list of journals, including types of articles published, requirements of authors for human-focused randomized control trials, JCR Impact Factor and other JCR metrics for each specific journal title. A worksheet was filled out for each journal by each member of the research team and answers combined for consensus. Group means and SDs were calculated and the Student’s t-Test applied to values for selected journals. Main Results: 50 candidate pharmacy journals were identified and 41 met the criteria for publishing human-centered randomized control trials. Journals were grouped according to whether they required CONSORT or had other reporting requirements for human RCTs, or had no requirements for such studies. Few (6; 15%) pharmacy journals required authors to use CONSORT; and additional 15 (37%) journals provided as least some author guidelines similar to CONSORT. Pharmacy journals using CONSORT or other guidelines had a higher average impact factor (3.5; SD = 1.5) than did journals without guidelines (2.4; SD = 0.9; p = 0.007). Conclusions: There appears to be a statistical difference in average JCR metrics between journals which require specific RCT guidelines and those which do not. The use of reporting guidelines, such as CONSORT, by pharmacy journals is associated with increased impact as represented by JCR influence measures.This item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Librarian and Clinical Instructor, Pharmacy Practice and Science, [email protected]
AESI Background Rates Literature Review & Visualitzation for ASM
No full textAESI Background Rates Literature Review & Visualitzation for ASMThe SPEAC Project is funded in whole by CEPI
Background rates literature review and visualization for Guillain Barré Syndrome (GBS)
No full textBackground rates literature review spreadsheet and visualization in forest plots for Guillain Barré Syndrome (GBS
Generalized convulsion: Background rates literature review and visualization
No full textAESI Background rates literature review and visualization for Generalized convulsio
Emerg Infect Dis
No full textWe describe 10 patients with nonkeratitis Acanthamoeba infection who reported performing nasal rinsing before becoming ill. All were immunocompromised, 7 had chronic sinusitis, and many used tap water for nasal rinsing. Immunocompromised persons should be educated about safe nasal rinsing to prevent free-living ameba infections
MMWR. Morbidity and Mortality Weekly Report, Vol. 71, No. 43, October 28, 2022
No full textInfluenza Incidence and Vaccine Effectiveness During the Southern Hemisphere Influenza Season \u2014 Chile, 2022 / Mar\ueda Fernanda Olivares Barraza; Rodrigo A Fasce; Francisco Nogareda; Perrine Marcenac et al. -- Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 \u2014 United States, January\u2013July 2022 / Tegan K. Boehmer; Emily H. Koumans; Elizabeth L. Skillen; Michael D. Kappelman et al. -- Vital Signs: Influenza Hospitalizations and Vaccination Coverage by Race and Ethnicity\u2014United States, 2009\u201310 Through 2021\u201322 Influenza Seasons / Carla L. Black; Alissa O\u2019Halloran; Mei-Chuan Hung; Anup Srivastav et al. --Receipt of First and Second Doses of JYNNEOS Vaccine for Prevention of Monkeypox \u2014 United States, May 22\u2013October 10, 2022 / Jennifer L. Kriss; Peter M. Boersma; Emalee Martin; Kirsten Reed et al. --Characteristics of JYNNEOS Vaccine Recipients Before and During a Large Multiday LGBTQIA+ Festival \u2014 Louisiana, August 9\u2013September 5, 2022 / Rieza H. Soelaeman; Lee Mendoza; Robert McDonald; Julie Hand et al. -- A Health Equity Approach for Implementation of JYNNEOS Vaccination at Large, Community-Based LGBTQIA+ Events \u2014 Georgia, August 27\u2013September 5, 2022 / Alexander J. Millman; Damian J. Denson; Michelle L. Allen; John A. Malone; Demetre C. Daskalakis et al. -- Notes From the Field: Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code\u2013Level Social Vulnerability \u2014 United States, December 23, 2021\u2013August 28, 2022 / Meg Sullivan; Cria G. Perrine; Jimmy Kelleher; Om Kanwar; Sachiko Kuwabara et al. --QuickStats: Age-Adjusted Death Rates for Stroke Among Adults Aged 65 65 Years, by Region and Metropolitan Status \u2014 National Vital Statistics System, United States, 2020
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
No full textReplication-deficient adenoviral vectors have been under investigation as a platform technology for vaccine development for several years and have recently been successfully deployed as an effective COVID-19 counter measure. A replication-deficient adenoviral vector based on the simian adenovirus type Y25 and named ChAdOx1 has been evaluated in several clinical trials since 2012. The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) was formed to evaluate the safety and other key features of new platform technology vaccines. This manuscript reviews key features of the ChAdOx1-vectored vaccines. The simian adenovirus Y25 was chosen as a strategy to circumvent pre-existing immunity to common human adenovirus serotypes which could impair immune responses induced by adenoviral vectored vaccines. Deletion of the E1 gene renders the ChAdOx1 vector replication incompetent and further genetic engineering of the E3 and E4 genes allows for increased insertional capability and optimizes vaccine manufacturing processes. ChAdOx1 vectored vaccines can be manufactured in E1 complementing cell lines at scale and are thermostable. The first ChAdOx1 vectored vaccines approved for human use, against SARS-CoV-2, received emergency use authorization in the UK on 30th December 2020, and is now approved in more than 180 countries. Safety data were compiled from phase I-III clinical trials of ChAdOx1 vectored vaccines expressing different antigens (influenza, tuberculosis, malaria, meningococcal B, prostate cancer, MERS-CoV, Chikungunya, Zika and SARS-CoV-2), conducted by the University of Oxford, as well as post marketing surveillance data for the COVID-19 Oxford-AstraZeneca vaccine. Overall, ChAdOx1 vectored vaccines have been well tolerated. Very rarely, thrombosis with thrombocytopenia syndrome (TTS), capillary leak syndrome (CLS), immune thrombocytopenia (ITP), and Guillain-Barre syndrome (GBS) have been reported following mass administration of the COVID-19 Oxford-AstraZeneca vaccine. The benefits of this COVID-19 vaccination have outweighed the risks of serious adverse events in most settings, especially with mitigation of risks when possible. Extensive immunogenicity clinical evaluation of ChAdOx1 vectored vaccines reveal strong, durable humoral and cellular immune responses to date; studies to refine the COVID-19 protection (e.g., via homologous/heterologous booster, fractional dose) are also underway. New prophylactic and therapeutic vaccines based on the ChAdOx1 vector are currently undergoing pre-clinical and clinical assessment, including vaccines against viral hemorrhagic fevers, Nipah virus, HIV, Hepatitis B, amongst others
